# US 2014/0154242 A1 · Immunoglobulin variants and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154242 A1
- Document ID: US20140154242A1
- Status: Published application
- Kind: A1
- Application number: 14/029,717
- Filed: 2013-09-17
- Published: 2014-06-05
- Earliest claimed: 2002-12-16
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Camellia W. ADAMS; Andrew C. Chan; Craig W. Crowley; Henry B. Lowman; Gerald R. Nakamura; Leonard G. Presta
- Web page: https://patentgrep.com/patent/US20140154242A1

## CPC

- C07K 16/2887: {against CD20}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/40: Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 13/12: of the kidneys
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/06: for tuberculosis
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/522: CH1 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

## Claims

### Claim at position 1

1-81. (canceled)

### Claim 82

A method of depleting B cells in vivo, comprising administering a humanized antibody that binds human CD20 to a mammal in an amount effective to deplete B cells, wherein the antibody comprises the VH sequence of SEQ ID NO. 8 and the VL sequence of SEQ ID NO. 2.

### Claim 83 (depends on 82)

The method of claim 82, wherein the antibody comprises the heavy chain and light chain amino acid sequences of SEQ ID NO. 39 and 40, respectively.

### Claim 84 (depends on 82)

The method of claim 82, wherein the antibody comprises the light chain and heavy chain amino acid sequences of SEQ ID NO. 40 and 41, respectively.

### Claim 85 (depends on 82)

The method of claim 82, wherein the antibody or the antigen-binding fragment is administered by intravenous infusion.

### Claim 86 (depends on 82)

The method of claim 82, wherein the antibody is administered subcutaneously.

### Claim 87 (depends on 82)

The method of claim 82, wherein the mammal is a human.

### Claim 88 (depends on 82)

The method of claim 82, wherein the peripheral B cells are depleted in the mammal.

### Claim 89 (depends on 82)

The method of claim 82, wherein the peripheral B cells are partially depleted.

### Claim 90

A method of depleting B cells in vivo, comprising administering an antigen-binding fragment of a humanized antibody to a mammal in an amount effective to deplete B cells, wherein the antigen-binding fragment comprises the CDR1 sequence of SEQ ID NO. 10, the CDR2 sequence of SEQ ID NO. 11, and the CDR3 sequence of SEQ ID NO. 12 in the heavy chain, and the CDR1 sequence of SEQ ID NO. 4, the CDR2 sequence of SEQ ID NO. 5, and the CDR3 sequence of SEQ ID NO. 6 in the light chain; wherein the humanized antibody comprises the heavy and light chain amino acid sequences of SEQ ID NO. 39 and 40, respectively.

### Claim 91 (depends on 90)

The method of claim 90, wherein the antigen-binding fragment is administered by intravenous infusion.

### Claim 92 (depends on 90)

The method of claim 90, wherein the antigen-binding fragment is administered subcutaneously.

### Claim 93 (depends on 90)

The method of claim 90, wherein the mammal is a human.

### Claim 94 (depends on 90)

The method of claim 90, wherein the peripheral B cells are depleted in the mammal.

### Claim 95 (depends on 90)

The method of claim 90, wherein the peripheral B cells are partially depleted.
